The US Food and Drug Administration is accelerating the review of several psychedelic-based therapies, signaling a shift in how mental health conditions may be treated. Under a new priority voucher program, companies researching psilocybin for depression and methylone for PTSD could see approval timelines reduced to as little as one to two months.
The move follows a broader federal push to expand research into promising treatments for conditions like treatment-resistant depression and substance use disorders. While early trial results appear encouraging, regulators stress that safety and rigorous clinical evidence remain essential.
Psychedelic drugs, still largely classified as high-risk substances, would only be administered in controlled clinical settings if approved. Experts say the initiative could expand access but caution that widespread adoption will take time. Full details are available via CNN.
